On May 29, the China (Shenzhen·Guangming) – Australia (New South Wales) Life and Health Industry Exchange Meeting took place at Weiguang Life Science Park in Guangming District, marking a significant step in strengthening ties between Shenzhen and Australia's leading life and health sectors.
The event brought together prominent Australian companies specializing in biomedicine, digital healthcare, and health services, along with top medical enterprises, institutions, and investors from Shenzhen.
Co-organized by the New South Wales Government and the Shenzhen Municipal Investment Promotion Bureau, and hosted by the Guangming District Government, the meeting emphasized deepening resource integration, technology exchange, and exploring market opportunities to usher in a new chapter of Sino-Australian cooperation.
Bilateral cooperation
The event saw 14 New South Wales biomedical and medical device companies engage with local partners to explore investment, commercialization, and market expansion opportunities in China's dynamic Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
New South Wales, home to Australia's largest medical technology industry centered in Sydney, is recognized globally for its medical research and biotech innovation. Leading companies including Cochlear, ResMed, and USCOM presented their projects at the meeting and expressed strong interest in partnering with Chinese counterparts.
Guangming has so far attracted over 1,500 multinational firms like GE Healthcare and Siemens, establishing itself as a strategic hub for global industrial and technological innovation.
The exchange deepened cooperation along the industry-academia-research-application chain. Guangming District officials pledged to support local companies in entering the Australian market to achieve synergy in technology, capital, and market access.
Iman Manavitehrani, co-founder and CSO of SDIP Innovations, told local media that he was impressed by the industry ecosystem here. “With the emphasis from both the New South Wales government and the Shenzhen government, having this collaboration, I am sure we can invent many new innovations, commercialize them, and help people,” he said.
Guangming's strong industrial foundation
Guangming has a strong industrial foundation in information technology, life sciences, and new materials, supported by robust funding and policies that encourage talent development and cross-border collaboration. Shenzhen's comprehensive pharmaceutical and medical device policies further bolster this ecosystem, focusing on R&D, AI applications, clinical trials, manufacturing, talent cultivation, and international expansion.
By 2024, the biomedicine cluster in Guangming included 35 major enterprises with an output exceeding 9.5 billion yuan, while over 800 high-end medical device companies contributed to a 50 billion yuan industry, featuring recognized specialized clusters in diagnostics and therapeutic equipment.
Guangming, Shenzhen's youngest district, is rapidly advancing toward becoming a world-class science city. With 22 major innovation platforms and collaborations among leading universities, research institutes, and enterprises, the district provides fertile ground for cutting-edge international scientific cooperation. Home to two provincial labs and two major research universities, Guangming has attracted nearly 190,000 professionals, including over 50 academicians, reinforcing its position as a hub of talent and innovation.